1. A composition comprising a glycosylated interferon-beta-1a with an amino acid sequence SEQ ID NO:25 coupled to a non naturally-occurring polymer at an N-terminal end of said glycosylated interferon-beta-1a, wherein said polymer comprising a polyalkylene glycol moiety. 2. The composition of claim 1, wherein the polyalkylene moiety is coupled to the interferon-beta-1a by way of a group selected from an aldehyde group, a maleimide group, a vinylsulfone group, a haloacetate group, plurality of histidine residues, a hydrazine group and an aminothiol group. 3. The composition of claim 1, wherein the glycosylated interferon-beta-1a is more active than interferon-beta-1 b when measured in an antiviral assay. 4. The composition of claim 3, wherein the interferon-beta-1a retains 50-100% the potency of interferon-beta-1a lacking said polymer, as measured in an antiviral assay. 5. A interferon-beta-1a composition of claim 1, wherein the polymer has a molecular weight of from about 5 to about 40 kilodaltons. 6. A pharmaceutical composition comprising the interferon-beta-1a composition of claim 5. 7. The composition, wherein comprising a mutant interferon-beta coupled to a non naturally-occurring polymer at an N-terminal end of said mutant interferon-beta, wherein said polymer comprising a polyalkylene glycol moiety, wherein said mutant interferon-beta is a peptide comprising an aminoacid sequence selected from the group comprising SEQ ID NO: 26-40. 8. A physiologically active interferon-beta composition comprising a physiologically active interferon-beta-1a with amino acid sequence SEQ ID NO: 25 coupled to a polymer comprising a polyalkylene glycol moiety, wherein the physiologically active interferon-beta 1a and the polyalkylene glycol moiety are arranged such that the physiologically active interferon-beta-1a in the physiologically active interferon-beta composition has an enhanced activity relative to physiologically active interferon-beta-1b, when measured by an antiviral
